These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6127352)

  • 1. Tardive dyskinesia in India: a prevalence study.
    Doongaji DR; Jeste DV; Jape NM; Sheth AS; Apte JS; Vahia VN; Desai AB; Vahora SA; Thatte S; Vevaina T; Bharadwaj J
    J Clin Psychopharmacol; 1982 Oct; 2(5):341-4. PubMed ID: 6127352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia and diabetes mellitus.
    Ganzini L; Casey DE; Hoffman WF; Heintz RT
    Psychopharmacol Bull; 1992; 28(3):281-6. PubMed ID: 1362276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and familial correlates of tardive dyskinesia in India and Israel.
    Bhatia T; Sabeeha MR; Shriharsh V; Garg K; Segman RH; Uriel HL; Strous R; Nimgaonkar VL; Bernard L; Deshpande SN
    J Postgrad Med; 2004; 50(3):167-72; discussion 172. PubMed ID: 15377799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.
    Bailey LG; Maxwell S; Brandabur MM
    Psychopharmacol Bull; 1997; 33(1):177-81. PubMed ID: 9133772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
    Ghadirian AM; Annable L; Bélanger MC; Chouinard G
    J Clin Psychiatry; 1996 Jan; 57(1):22-8. PubMed ID: 8543543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.
    Harris MJ; Panton D; Caligiuri MP; Krull AJ; Tran-Johnson TK; Jeste DV
    Psychopharmacol Bull; 1992; 28(1):87-92. PubMed ID: 1609047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
    Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
    Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A summary of current knowledge of tardive dyskinesia.
    Baldessarini RJ
    Encephale; 1988 Sep; 14 Spec No():263-8. PubMed ID: 2905654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of tardive dyskinesia.
    Woerner MG; Kane JM; Lieberman JA; Alvir J; Bergmann KJ; Borenstein M; Schooler NR; Mukherjee S; Rotrosen J; Rubinstein M
    J Clin Psychopharmacol; 1991 Feb; 11(1):34-42. PubMed ID: 1674949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence.
    Kane JM
    J Clin Psychiatry; 2004; 65 Suppl 9():16-20. PubMed ID: 15189107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study.
    Raja M; Azzoni A
    Hum Psychopharmacol; 2002 Jan; 17(1):61-3. PubMed ID: 12404708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
    Achalia RM; Chaturvedi SK; Desai G; Rao GN; Prakash O
    Asian J Psychiatr; 2014 Jun; 9():31-5. PubMed ID: 24813033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.
    Chouinard G; Annable L; Ross-Chouinard A; Mercier P
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):21S-26S. PubMed ID: 3220967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland].
    Gałecki P; Pietras T; Szemraj J
    Psychiatr Pol; 2006; 40(5):937-48. PubMed ID: 17217237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
    Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Mukit SR; Shriharsh V; Lerer B; Nimagaonkar VL; Thelma BK
    Pharmacogenomics J; 2005; 5(1):60-9. PubMed ID: 15505641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroleptic-induced tardive dyskinesias in France].
    Bourgeois M
    Encephale; 1988 Sep; 14 Spec No():195-201. PubMed ID: 2905646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tardive dyskinesia: a review].
    Crespo Facorro B; Payá González B; Ruiz Fernández V; Carbonell Masia C
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(2):118-27. PubMed ID: 9245189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.